Provider Briefing: Bss Ophthalmic Solution Supply in 2026

Bss Ophthalmic Solution — the sterile balanced salt irrigating solution critical to nearly every intraocular surgical procedure — has been subject to intermittent supply constraints for several years. As a provider or prescriber in ophthalmology, understanding the current landscape is essential for surgical planning, patient communication, and operational continuity.

This briefing covers the supply timeline, prescribing implications, current availability picture, cost considerations, and tools to help your practice navigate these challenges.

Supply Timeline: How We Got Here

The Bss Ophthalmic Solution supply story is fundamentally a story of market concentration driven by regulatory action:

• 1960s: Balanced salt solution developed as a safer alternative to normal saline for intraocular irrigation
• 1990s-2000s: Multiple manufacturers produced BSS formulations, many without FDA approval
• 2008: FDA published enforcement action dates for unapproved ophthalmic balanced salt solutions, restricting the market to products with valid NDAs — primarily Alcon's BSS (NDA 20-742) and BSS Plus (NDA 18-469)
• 2008-2024: Market consolidation around Alcon as the dominant FDA-approved supplier, with periodic supply tightness when production could not meet growing demand
• 2025-2026: Continued intermittent supply constraints as cataract surgery volumes exceed 4 million procedures annually in the U.S., straining Alcon's manufacturing capacity

The regulatory rationale was sound — ensuring sterility and quality of products used inside the eye is critical for patient safety. However, the unintended consequence has been a near-monopoly supply situation that leaves the entire surgical ophthalmology community vulnerable to single-manufacturer disruptions.

Prescribing and Surgical Implications

For ophthalmologists and surgical teams, the BSS supply situation creates several practical challenges:

Surgical Scheduling

Supply uncertainty can force last-minute surgical cancellations or rescheduling, which impacts patient care, practice revenue, and operating room efficiency. Practices should consider:

• Confirming BSS inventory at least 1-2 weeks before scheduled surgical days
• Maintaining buffer stock when possible (recognizing this may not always be feasible)
• Establishing relationships with multiple medical supply distributors

Product Selection

Understanding the differences between available products is critical for appropriate substitution:

• BSS (standard): Approved for intraocular procedures under 60 minutes. Contains balanced electrolytes (NaCl, KCl, CaCl₂, MgCl₂, sodium acetate, sodium citrate)
• BSS Plus: Approved for procedures of any duration. Additionally contains sodium bicarbonate, dextrose, and glutathione oxidized. Provides superior corneal endothelial protection for extended procedures
• Endosol Extra: Alternative balanced salt solution for intraocular use with similar electrolyte profile

Documentation and Communication

When substituting products due to supply constraints, ensure:

• Surgical consent forms reflect the actual product to be used
• Operative notes document the specific irrigating solution and lot number
• Patients are informed of any product substitution and its rationale

Current Availability Picture

As of early 2026, Bss Ophthalmic Solution availability varies significantly by region and facility type:

• Hospital-based programs: Generally better positioned due to larger purchasing agreements, group purchasing organization (GPO) contracts, and deeper inventory buffers
• Ambulatory surgery centers (ASCs): More vulnerable to supply fluctuations, particularly independent ASCs with limited purchasing leverage
• Academic medical centers: Typically maintain larger inventories and have established relationships with Alcon's institutional sales team
• Rural facilities: May experience longer supply gaps due to distribution logistics

Providers can use tools like Medfinder for Providers to check real-time availability at nearby suppliers and coordinate sourcing efforts.

Cost and Access Considerations

Current pricing for Bss Ophthalmic Solution reflects the concentrated market:

• BSS (Alcon brand): $80-$150 per 500 mL
• BSS Plus (Alcon brand): $90-$150 per 500 mL
• Generic balanced salt solution: $40-$80 per 500 mL (limited FDA-approved sources)

For most patients, BSS costs are absorbed into facility fees covered by medical insurance. However, providers should be aware that:

• Rising BSS costs contribute to overall surgical supply expenses
• Uninsured or underinsured patients facing out-of-pocket surgical costs are indirectly affected
• Some facilities have explored cost-sharing arrangements with alternative suppliers

For patient-facing cost guidance, refer patients to our article on how to save money on Bss Ophthalmic Solution.

Tools and Resources for Providers

Several tools can help practices manage BSS supply challenges:

Medfinder for Providers

Medfinder's provider platform offers real-time availability tracking for Bss Ophthalmic Solution and related surgical supplies across multiple distributors. This can reduce time spent on phone calls to suppliers and help identify alternative sources quickly.

ASHP Drug Shortage Database

The American Society of Health-System Pharmacists maintains a drug shortage database that tracks formally reported shortages. While BSS may not always appear on this list, checking it provides context on broader ophthalmic supply trends.

FDA Drug Shortage Database

The FDA's shortage database provides official information on shortage status and expected resolution timelines. Monitoring this resource helps practices plan ahead.

Distributor Relationships

Maintaining accounts with multiple medical supply distributors (not just one) can provide backup sourcing options. Consider establishing relationships with:

• National distributors (McKesson, Cardinal Health, Medline)
• Regional specialty ophthalmic distributors
• Direct ordering through Alcon's institutional sales channel

Looking Ahead

The BSS supply situation is unlikely to resolve quickly, but several developments may gradually improve conditions:

• Potential new FDA approvals: The FDA has indicated openness to approving additional BSS manufacturers, which would diversify supply. The approval timeline for sterile ophthalmic products is lengthy, however.
• Alcon capacity expansion: Alcon has invested in manufacturing capacity, though details on BSS-specific production increases are not publicly available.
• Industry advocacy: Professional organizations including the American Academy of Ophthalmology continue to engage with the FDA and manufacturers on supply security for essential surgical products.

Providers should plan for continued intermittent supply constraints throughout 2026 and into 2027. Building resilient supply chains, maintaining flexible surgical schedules, and leveraging tools like Medfinder for Providers will be essential strategies.

Final Thoughts

The Bss Ophthalmic Solution shortage is a complex issue rooted in regulatory market concentration, rising surgical demand, and supply chain fragility. As providers, the priority is ensuring patient care continues without interruption while advocating for a more resilient supply landscape.

Stay informed, maintain multiple sourcing channels, and communicate transparently with patients about any scheduling impacts. For a patient-facing perspective on this issue, see our patient shortage update, and for guidance on helping patients locate BSS, read our provider's guide to helping patients find Bss Ophthalmic Solution.